Enhancing Malaria Control in West Africa: Combining Non-Pyrethroid Indoor Residual Spraying or Intensive Behaviour Change Communication with Long-Lasting Insecticidal Nets
Posted inClinical Updates Public Health Specialties

Enhancing Malaria Control in West Africa: Combining Non-Pyrethroid Indoor Residual Spraying or Intensive Behaviour Change Communication with Long-Lasting Insecticidal Nets

This trial shows that adding non-pyrethroid indoor residual spraying (IRS) or intensive behaviour change communication (BCC) to long-lasting insecticidal nets (LLINs) reduces malaria incidence by over 20% in West African rural communities, highlighting promising integrated malaria control strategies.
Advancing Treatment in Oligometastatic Castration-Resistant Prostate Cancer: The GROUQ-PCS 9 Trial on SBRT Plus Standard Systemic Therapy
Posted inClinical Updates Oncology Specialties Urology

Advancing Treatment in Oligometastatic Castration-Resistant Prostate Cancer: The GROUQ-PCS 9 Trial on SBRT Plus Standard Systemic Therapy

The GROUQ-PCS 9 trial demonstrates that adding stereotactic body radiotherapy to standard androgen deprivation therapy and enzalutamide significantly prolongs radiographic progression-free survival in oligometastatic castration-resistant prostate cancer with manageable toxicity.
Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial
Posted inClinical Updates news Oncology Specialties

Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial

The PECATI phase 2 trial demonstrates that lenvatinib combined with pembrolizumab offers encouraging antitumour activity and a manageable safety profile in platinum-refractory metastatic B3 thymoma and thymic carcinoma, a population with limited treatment options.
Posted inClinical Updates Hematology-Oncology news Specialties

Enhanced Progression-Free Survival with Ibrutinib Plus Rituximab in CXCR4-Mutated Waldenström Macroglobulinemia: Insights from a Pooled Analysis

A pooled analysis of prospective studies shows ibrutinib plus rituximab improves progression-free survival in Waldenström macroglobulinemia patients with CXCR4 mutations compared to ibrutinib alone, supporting routine CXCR4 testing and combination treatment strategies.
Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study
Posted inClinical Updates Hematology-Oncology Specialties

Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study

Maintenance therapy with romidepsin following autologous hematopoietic stem-cell transplantation (AHCT) in peripheral T-cell lymphoma (PTCL) demonstrated feasibility and an estimated 2-year progression-free survival (PFS) of 62%, though the primary efficacy endpoint was not met in this phase 2 trial.